Bli medlem
Bli medlem

Du är här

2016-09-13

Nordic Nanovector: NORDIC NANOVECTOR ASA -NOTIFICATION OF SHARE CAPITAL INCREASE

Date: 13.09.2016        Press Release no: 44/2016

Reference is made to the notification sent to Oslo Børs 30 August 2016
regarding the issuance of new shares in Nordic Nanovector ASA (The
"Company") in connection with the exercise of 3,000 options.

The share capital increase was registered in the Norwegian Business
Register on 13 September 2016. The Company's share capital is
following the share capital increase NOK 8,920,074.8 divided by
44,600,374 shares each with a nominal value of NOK 0.20.

This information is disclosed in accordance with the Norwegian
Securities Trading Act section 5-8.

For further information, please contact:
IR enquiries:
Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com

About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company's lead clinical-stage product opportunity is
Betalutin®, the first in a new class of
Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and
complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and
orphan drug opportunities, representing a growing market worth over
$12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab
(previously referred to as HH1), conjugated to a low intensity
radionuclide (lutetium-177). The preliminary data has shown promising
efficacy and safety profile in an ongoing Phase 1/2 study in a
difficult-to-treat NHL patient population. The Company is aiming at
developing Betalutin® for the treatment of major types of NHL with
first regulatory submission anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets,
while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline
to treat multiple selected cancer indications.

Further information about the Company can be found at
www.nordicnanovector.com

-----------------------------------------------------------
http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--notifi...

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.